Eupraxia Pharmaceuticals Inc. (EPRX)
NASDAQ: EPRX · Real-Time Price · USD
8.06
+0.43 (5.64%)
Nov 11, 2026, 4:00 PM EST - Market closed
Eupraxia Pharmaceuticals Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 75.18 | 80.56 | 33.1 | 19.34 | 18.26 | 16.51 |
Short-Term Investments | 51.25 | - | - | - | - | 7.12 |
Cash & Short-Term Investments | 126.42 | 80.56 | 33.1 | 19.34 | 18.26 | 23.63 |
Cash Growth | 42.11% | 143.39% | 71.14% | 5.91% | -22.70% | 19954.27% |
Other Receivables | 0.2 | 0.67 | 0.23 | 0.19 | 0.09 | 0.34 |
Receivables | 0.2 | 0.67 | 0.23 | 0.19 | 0.09 | 0.34 |
Prepaid Expenses | 3.33 | 3.86 | 1.11 | 0.27 | 0.24 | 0.21 |
Total Current Assets | 129.95 | 85.1 | 34.44 | 19.8 | 18.59 | 24.18 |
Property, Plant & Equipment | 4.56 | 0.99 | 0.42 | 0.46 | 0.53 | 0.47 |
Other Long-Term Assets | 0.05 | 0.06 | 0.08 | 0.01 | 0 | 0.02 |
Total Assets | 134.56 | 86.15 | 34.94 | 20.27 | 19.12 | 24.67 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accrued Expenses | - | 5.51 | 3.01 | 3.87 | 2.91 | 1.67 |
Current Portion of Long-Term Debt | - | - | - | 10.4 | 0.08 | 0.08 |
Current Portion of Leases | 0.51 | 0.08 | 0.07 | 0.05 | 0.05 | 0.05 |
Current Income Taxes Payable | - | 0 | - | 0.04 | - | - |
Other Current Liabilities | - | 0.04 | 0.02 | 5.02 | 0.02 | 0 |
Total Current Liabilities | 10.61 | 5.63 | 3.1 | 19.37 | 3.06 | 1.79 |
Long-Term Debt | - | - | - | - | 8.8 | 7.66 |
Long-Term Leases | 2.91 | 0.08 | - | - | 0.05 | 0.11 |
Total Liabilities | 13.52 | 5.7 | 3.1 | 19.37 | 11.91 | 9.56 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 276.05 | 195.41 | 116.36 | 92.91 | 71 | 61.36 |
Additional Paid-In Capital | 34.15 | 28.52 | 20.5 | 17.51 | 16.85 | - |
Retained Earnings | -211.96 | -169.58 | -131 | -105.5 | -77.28 | -58.68 |
Comprehensive Income & Other | -6.71 | -2.04 | -4.16 | -2.71 | -2.79 | 13.09 |
Total Common Equity | 91.52 | 52.3 | 1.7 | 2.22 | 7.79 | 15.77 |
Minority Interest | - | -1.6 | -1.57 | -1.32 | -0.58 | -0.66 |
Shareholders' Equity | 121.05 | 80.45 | 31.84 | 0.89 | 7.21 | 15.11 |
Total Liabilities & Equity | 134.56 | 86.15 | 34.94 | 20.27 | 19.12 | 24.67 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 3.42 | 0.15 | 0.07 | 10.45 | 8.99 | 7.9 |
Net Cash (Debt) | 123 | 80.41 | 33.03 | 8.89 | 9.28 | 15.73 |
Net Cash Growth | 38.53% | 143.45% | 271.55% | -4.18% | -41.03% | - |
Net Cash Per Share | 2.03 | 2.01 | 0.97 | 0.37 | 0.48 | 1.27 |
Filing Date Shares Outstanding | 67.24 | 61.5 | 35.85 | 35.62 | 27.36 | 14.24 |
Total Common Shares Outstanding | 67.24 | 51.94 | 35.64 | 27.28 | 21.59 | 14.24 |
Working Capital | 119.35 | 79.47 | 31.33 | 0.43 | 15.53 | 22.39 |
Book Value Per Share | 1.36 | 1.01 | 0.05 | 0.08 | 0.36 | 1.11 |
Tangible Book Value | 91.52 | 52.3 | 1.7 | 2.22 | 7.79 | 15.77 |
Tangible Book Value Per Share | 1.36 | 1.01 | 0.05 | 0.08 | 0.36 | 1.11 |
Buildings | - | - | - | - | - | 0.07 |
Machinery | - | 1.35 | 0.7 | 0.68 | 0.61 | 0.1 |
Leasehold Improvements | - | 0.13 | 0.12 | 0.13 | 0.13 | 0.13 |